Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer: Safety lead‐in results from the QUATTRO-II study

Daisuke Kotani, Takayuki Yoshino, Masahito Kotaka, Akihito Kawazoe, Toshiki Masuishi, Hiroya Taniguchi, Kentaro Yamazaki, Takeharu Yamanaka, Eiji Oki, Kei Muro, Yoshito Komatsu, Hideaki Bando, Hironaga Satake, Takeshi Kato, Akihito Tsuji

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer: Safety lead‐in results from the QUATTRO-II study'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science